HALO (Halozyme Therapeutics) Future 3-5Y EPS without NRI Growth Rate : 23.93 (As of Mar. 05, 2025)

View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate is 23.93.

Competitive Comparison of Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Halozyme Therapeutics (NAS:HALO) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Halozyme Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

0J2O:UK RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Executives

Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Michael J. Labarre	officer: SVP, Chief Technical Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley	director, officer: President and CEO	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Nicole Labrosse	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Akiko Moni Miyashita	director	20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley	director	1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey	officer: SVP, Chief Commerical Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121